Engineered immune cells take aim at lupus and MS
NCT ID NCT06775912
First seen Feb 02, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-stage study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune cells in autoimmune diseases. The trial includes 18 adults with conditions like lupus, systemic sclerosis, multiple sclerosis, and others. The main goal is to check safety and how the body handles the therapy, with early signs of effectiveness also being tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First People's Hospital of Lianyungang
RECRUITINGLianyungang, Jiangus, 222000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.